- Home
- ADXN vs AYTU Comparison
ADXN vs AYTU Comparison
Compare ADXN & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADXN
- AYTU
- Stock Information
- Founded
- ADXN 2002
- AYTU N/A
- Country
- ADXN Switzerland
- AYTU United States
- Employees
- ADXN N/A
- AYTU N/A
- Industry
- ADXN Biotechnology: Pharmaceutical Preparations
- AYTU Biotechnology: Pharmaceutical Preparations
- Sector
- ADXN Health Care
- AYTU Health Care
- Exchange
- ADXN Nasdaq
- AYTU Nasdaq
- Market Cap
- ADXN 8.1M
- AYTU 8.3M
- IPO Year
- ADXN N/A
- AYTU N/A
- Fundamental
- Price
- ADXN $8.12
- AYTU $2.59
- Analyst Decision
- ADXN Strong Buy
- AYTU
- Analyst Count
- ADXN 1
- AYTU 0
- Target Price
- ADXN $30.00
- AYTU N/A
- AVG Volume (30 Days)
- ADXN 3.0K
- AYTU 3.4M
- Earning Date
- ADXN 06-05-2025
- AYTU 05-14-2025
- Dividend Yield
- ADXN N/A
- AYTU N/A
- EPS Growth
- ADXN N/A
- AYTU N/A
- EPS
- ADXN 0.06
- AYTU N/A
- Revenue
- ADXN $701,260.00
- AYTU $77,232,000.00
- Revenue This Year
- ADXN N/A
- AYTU N/A
- Revenue Next Year
- ADXN N/A
- AYTU $8.14
- P/E Ratio
- ADXN $1.06
- AYTU N/A
- Revenue Growth
- ADXN N/A
- AYTU N/A
- 52 Week Low
- ADXN $6.51
- AYTU $0.95
- 52 Week High
- ADXN $13.27
- AYTU $3.45
- Technical
- Relative Strength Index (RSI)
- ADXN 54.21
- AYTU 82.21
- Support Level
- ADXN $7.70
- AYTU $1.20
- Resistance Level
- ADXN $8.38
- AYTU $1.31
- Average True Range (ATR)
- ADXN 0.32
- AYTU 0.13
- MACD
- ADXN 0.01
- AYTU 0.05
- Stochastic Oscillator
- ADXN 59.13
- AYTU 74.52
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.